It is increasingly apparent that not only is a cure for the current worldwide diabetes epidemic
required, but also for its major complications, affecting both small and large blood vessels …

Objectives To synthesise current evidence for the effects of exenatide and liraglutide on
heart rate, blood pressure and body weight. Design Meta-analysis of available data from …

Background Glucagon-like peptide-1 receptor agonists exenatide and liraglutide have been
shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes …

Two general approaches to the treatment of type 2 diabetes mellitus (T2DM) have been
advocated. 1) A “guideline” approach that advocates sequential addition of antidiabetes …

There is no question that incretin-based glucose-lowering medications have proven to be
effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor agonists …

OBJECTIVE To compare efficacy and safety of lixisenatide once daily versus exenatide
twice daily in type 2 diabetes inadequately controlled with metformin. RESEARCH DESIGN …

Aims Aside from lowering blood glucose, glucagon‐like peptide‐1 receptor agonists (GLP‐1
RAs) attract much attention because of their cardioprotective effects. The aim of this study …

Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk
for a broad range of adverse cardiovascular outcomes including coronary heart disease …

There is no question that incretin-based glucose-lowering medications have proven to be
effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor agonists …

Aims To investigate efficacy and safety of dual therapy with liraglutide and metformin in
comparison to glimepiride and metformin, and metformin monotherapy over 2 years in …